PTGS2 and neoplasm: Additionally, the drug alleviates the inhibition of T cell activity by interfering with the COX-2/PGE2/IDO1 axis and inhibiting abnormal tryptophan metabolism in tumor-associated neutrophils (TANs) (Ouyang et al., 2024).